Alnylam Pharmaceuticals, Inc.
ALNY
$473.29
$8.361.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 149.35% | 17.26% | 20.20% | 34.90% | -33.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 149.35% | 17.26% | 20.20% | 34.90% | -33.26% |
| Cost of Revenue | 132.99% | 108.17% | 7.68% | 19.75% | 1.89% |
| Gross Profit | 152.73% | 6.70% | 22.13% | 38.57% | -37.71% |
| SG&A Expenses | 45.74% | 30.16% | 13.83% | 49.07% | 10.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.48% | 29.23% | 7.13% | 25.57% | 7.67% |
| Operating Income | 578.49% | -133.32% | 141.62% | 9.66% | -135.96% |
| Income Before Tax | 319.92% | -216.63% | 34.58% | -40.87% | -172.09% |
| Income Tax Expenses | -516.75% | 440.35% | 576.45% | -60,315.85% | -2.71% |
| Earnings from Continuing Operations | 325.05% | -292.43% | 12.82% | 39.24% | -175.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 325.05% | -292.43% | 12.82% | 39.24% | -175.51% |
| EBIT | 578.49% | -133.32% | 141.62% | 9.66% | -135.96% |
| EBITDA | 706.75% | -103.54% | 208.57% | 11.59% | -127.70% |
| EPS Basic | 320.17% | -280.65% | 15.19% | 40.90% | -173.53% |
| Normalized Basic EPS | 354.06% | -236.85% | 37.91% | -36.17% | -162.22% |
| EPS Diluted | 311.49% | -280.65% | 15.19% | 40.90% | -175.53% |
| Normalized Diluted EPS | 343.15% | -236.85% | 37.91% | -36.17% | -165.27% |
| Average Basic Shares Outstanding | 2.22% | 3.07% | 2.80% | 2.79% | 2.69% |
| Average Diluted Shares Outstanding | 6.81% | 3.07% | 2.80% | 2.79% | -2.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |